# 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

> **NCT04689347** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 27 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** 5Fluorouracil
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04689347
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-01-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04689347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04689347, "5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04689347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*